Health Canada approves XERMELO™ (telotristat ethyl)

Health Canada approves XERMELO™ (telotristat ethyl) for the treatment of adult patients suffering from refractory carcinoid syndrome diarrhea(1) "XERMELOTM is a novel, orally administered, inhibitor of the enzyme tryptophan hydroxylase [...]

By |2018-10-17T14:45:09+00:00October 17th, 2018|Treatment News|Comments Off on Health Canada approves XERMELO™ (telotristat ethyl)

Public Listings for Caprelsa

Caprelsa (vandetanib) is indicated for the treatment of symptomatic or progressive Medullary thyroid cancer in adult patients with unresectable locally advanced or metastatic disease. Alberta Health Services has put the [...]

By |2018-09-18T23:32:14+00:00September 18th, 2018|Treatment News|Comments Off on Public Listings for Caprelsa

Patient Input – Treatment with Telotristat

TELOTRISTAT is an adjunct to somatostatin analogue therapy for the long-term treatment of carcinoid syndrome to improve symptom control in adult patients with metastatic neuroendocrine tumours.The company who makes telotristat [...]

By |2018-09-03T18:47:17+00:00September 3rd, 2018|Survey, Treatment News|Comments Off on Patient Input – Treatment with Telotristat

NET Research Priorities Survey Results

In March CNETS Canada reached out to the patient community through an online, anonymous survey to gather feedback and input on setting the research priorities for CNETS Canada sponsored grants [...]

By |2018-09-22T00:19:01+00:00August 15th, 2018|Research, Survey|Comments Off on NET Research Priorities Survey Results

PRRT Program at L’Hôtel-Dieu de Québec

Une approche novatrice contre le cancer à l'Hôtel-Dieu de Québec « Une nouvelle approche médicale attire à Québec des Canadiens, et même des Américains, atteints d'une forme rare de cancer. Le traitement [...]

By |2018-06-19T15:58:17+00:00June 19th, 2018|News|Comments Off on PRRT Program at L’Hôtel-Dieu de Québec
Go to Top